Dr. Colleen Kelly

---

Medical Degree: Ohio State University
Residency: Boston Medical Center
Fellowship: Rhode Island Hospital, The Warren Alpert Medical School of Brown University

The focus of Dr. Kelly’s research and clinical practice is Clostridium difficile infection (CDI) and fecal microbiota transplantation (FMT).  She was the principal investigator (PI) for a first placebo-controlled trial of FMT for treatment of recurrent CDI and one of the first investigators to sponsor of an investigational new drug (IND) application for FMT with the Food and Drug Administration. She has since served on several working groups focusing on regulatory issues related to FMT.  Dr. Kelly is currently site PI for an industry funded trial of live microbiota for treatment of recurrent CDI as well as investigator-initiated clinical trials assessing conventional FMT for CDI treatment. Dr. Kelly is interested in the long-term effects around manipulation of gut microbiota and serves as one of the PIs for an NIH-funded FMT National Registry which will answer important questions around the safety of FMT.  She has collaborated on several studies investigating the impact of FMT on patients with Inflammatory Bowel Disease, Nonalcoholic Fatty Liver Disease and Alopecia Areata.  In addition to coauthoring current FMT guidelines and participating in drafting the European Consensus Conference on Fecal Microbiota Transplant in Clinical Practice, she serves as the primary author for the forthcoming American College of Gastroenterology (ACG) 2019 C. difficile treatment guidelines.  Dr. Kelly is a Fellow in the ACG and is a Fellow and past member of the scientific advisory board for Gut Microbiome Research and Education of the American Gastroenterological Association.